Targeted development of biosimilar pharmaceutical products

More documents

Recommendations

Info

Thanks for listening! Thanks for contributing! Mengeš, Schaftenau & Kundl, Oberhaching & Holzkirchen 34 | Thomas Stangler | EAPB SIG Regulatory Aspects for Bio<strong>pharmaceutical</strong>s | October 4th, 2010 | Business use only
Page 1 and 2: Targeted development of biosimilar
Page 3 and 4: Sandoz and Novartis have cutting ed
Page 5 and 6: …and are produced from geneticall
Page 7 and 8: Biosimilars development is a hybrid
Page 9 and 10: Biosimilars: The Regulatory Landsca
Page 11 and 12: Quality: A full quality dossier sup
Page 13 and 14: Biosimilars are recognized around t
Page 15 and 16: Target-directed product development
Page 17 and 18: Starting a biosimilar development p
Page 19 and 20: ICH Q8, Q9 and Q10 19 | Thomas Stan
Page 21 and 22: Elements of QbD Pharmaceutical Deve
Page 23 and 24: Typical product quality attributes
Page 25 and 26: Factors Impacting Quality: Curse or
Page 27 and 28: Targeted cell line development: Dri
Page 29 and 30: Charge variant (%) 80 60 40 20 0 Ta
Page 31 and 32: QbD for Biosimilars and novel Bioph
Page 33: Final remarks! � Biosimilars are

Targeted development of biosimilar pharmaceutical products

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?